Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$683.64B | 63.6x | 0.78 | US$761.85 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.6% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$360.89B | 16.5x | -0.4 | US$150.05 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$327.24B | 78.9x | -2.6 | US$185.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.5% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$325.83B | 20.4x | 1.14 | US$73.67 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$269.40B | 26.8x | -0.9 | US$315.71 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$269.18B | 26.8x | -0.9 | US$39.49 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.3% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$227.27B | 18.2x | -1.33 | US$116.13 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$226.89B | 18.2x | -1.33 | US$116.22 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.1% Downside | Upgrade to Pro+ | |
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$217.91B | 28.4x | 1.24 | US$70.43 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.6% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$217.47B | 28.4x | 1.24 | US$143.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$198.10B | 11.4x | 0.02 | US$79.05 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.5% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$156.26B | 26.3x | 0.47 | US$291.17 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$135.88B | 17.2x | 0.01 | US$23.96 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.3% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$134.28B | 22.5x | 0.02 | US$108.08 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.7% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$116.88B | 16.7x | 0.41 | US$47.97 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.5% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Pharmaceuticals | US$113.47B | -112.4x | 0.93 | US$441.98 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.3% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$95.65B | 17.6x | 0.09 | US$47.03 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$90.71B | 28.1x | 1.86 | US$728.39 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$81.81B | 28.9x | 1.12 | US$25.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | US$76.96B | 18.6x | -0.62 | US$19.51 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | US$76.86B | 18.6x | -0.62 | US$38.26 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.5% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$75.56B | 27.5x | 2.43 | US$78.20 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.6% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | US$69.65B | 27.9x | 3.74 | US$156.16 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | US$55.15B | 17x | 4.88 | US$25.41 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.8% Upside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | US$46.37B | 25x | 0.62 | US$10.52 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.9% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | US$46.13B | 62.8x | -2.33 | US$28.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | US$46.13B | 62.8x | -2.36 | US$14.80 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | US$42.73B | 21.3x | 0.43 | US$22.89 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alnylam | NASDAQ | Healthcare | Pharmaceuticals | US$40.87B | -149x | -7.27 | US$313.48 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5% Upside | Upgrade to Pro+ | |
Cardinal Health | NYSE | Healthcare | Pharmaceuticals | US$39.36B | 25.8x | 0.16 | US$164.68 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.8% Upside | Upgrade to Pro+ | |
UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | US$34.37B | 28.2x | 0.13 | US$90.44 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.4% Upside | Upgrade to Pro+ | |
Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | US$30.30B | -8.1x | 1.8 | US$7.69 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | US$25.17B | 10.7x | 0.07 | US$24.02 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.3% Upside | Upgrade to Pro+ | |
Sandoz | OTC Markets | Healthcare | Pharmaceuticals | US$23.01B | US$51.98 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.6% Upside | Upgrade to Pro+ | |||
Teva ADR | NYSE | Healthcare | Pharmaceuticals | US$19.57B | -15.8x | 0.09 | US$17.04 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.8% Upside | Upgrade to Pro+ | |
Royalty Pharma | NASDAQ | Healthcare | Pharmaceuticals | US$19.41B | 14x | 0.36 | US$34.46 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.3% Upside | Upgrade to Pro+ | |
Biogen | NASDAQ | Healthcare | Pharmaceuticals | US$18.68B | 12.5x | 0.47 | US$127.22 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.4% Upside | Upgrade to Pro+ | |
Astellas Pharma Inc | OTC Markets | Healthcare | Pharmaceuticals | US$16.68B | 47.8x | 0.24 | US$9.27 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
Shionogi ADR | OTC Markets | Healthcare | Pharmaceuticals | US$14.57B | 12.5x | 1.62 | US$8.61 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.5% Upside | Upgrade to Pro+ | |
Incyte | NASDAQ | Healthcare | Pharmaceuticals | US$13.15B | 621.2x | -6.4 | US$67.86 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6% Upside | Upgrade to Pro+ | |
United Therapeutics | NASDAQ | Healthcare | Pharmaceuticals | US$13.02B | 10.6x | 0.58 | US$289.04 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.1% Upside | Upgrade to Pro+ | |
Dr. Reddy’s Labs ADR | NYSE | Healthcare | Pharmaceuticals | US$12.74B | 19.6x | 13.27 | US$15.33 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.5% Upside | Upgrade to Pro+ | |
Neurocrine | NASDAQ | Healthcare | Pharmaceuticals | US$12.57B | 41.6x | -2.3 | US$127.15 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.7% Upside | Upgrade to Pro+ | |
CSPC Pharmaceutical Group | OTC Markets | Healthcare | Pharmaceuticals | US$11.07B | 19.2x | -0.64 | US$1.05 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin Pharma | NASDAQ | Healthcare | Pharmaceuticals | US$10.68B | 20.1x | 0.13 | US$55.77 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion ADR | OTC Markets | Healthcare | Pharmaceuticals | US$10.31B | 25.9x | 0.42 | US$35.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viatris | NASDAQ | Healthcare | Pharmaceuticals | US$10.30B | -2.8x | 0 | US$8.79 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.8% Upside | Upgrade to Pro+ | |
Ipsen ADR | OTC Markets | Healthcare | Pharmaceuticals | US$9.59B | 23.7x | -0.51 | US$29.34 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols ADR | NASDAQ | Healthcare | Pharmaceuticals | US$8.04B | 35.5x | US$8.80 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.1% Upside | Upgrade to Pro+ | ||
Grifols ADR | OTC Markets | Healthcare | Pharmaceuticals | US$8.04B | 35.5x | US$6.14 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |